Ensartinib treatment for ALK positive lung cancer after surgery

A Phase Ⅲ, Double-blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of Ensartinib Versus Placebo as Adjuvant Therapy in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Stage IB- IIIB Non-small Cell Lung Cancer.

This study is testing if the drug ensartinib can help people with ALK positive lung cancer stay cancer-free after surgery compared to a placebo.

Quick facts

• Phase: Phase 3
• Study type: Interventional
• Enrollment: 202 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Betta Pharmaceuticals Co., Ltd. (Industry-sponsored)
• Drugs / interventions: chemotherapy, immunotherapy, ensatinib
• Locations: 1 site (Tianjin)
• Trial ID: NCT05341583 on ClinicalTrials.gov

What this trial studies

This Phase III clinical trial is a double-blind, randomized, placebo-controlled study aimed at evaluating the efficacy and safety of ensartinib as an adjuvant treatment for patients with ALK positive stage II-IIIB non-small cell lung cancer following surgical resection. Participants will be assigned to receive either ensartinib or a placebo for a duration of two years, with the primary endpoint being disease-free survival. The study will monitor participants until disease recurrence or the maximum treatment duration is reached, followed by a survival follow-up period.

Who should consider this trial

Good fit: Ideal candidates include patients with histologically confirmed ALK positive non-small cell lung cancer who have undergone complete surgical resection and are classified as Stage IB-IIIB.

Not a fit: Patients with non-ALK positive lung cancer or those who have not undergone complete surgical resection may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve disease-free survival rates for patients with ALK positive non-small cell lung cancer.

How similar studies have performed: Other studies have shown promising results with similar adjuvant treatments for lung cancer, indicating potential for success in this approach.

Eligibility criteria

Inclusion Criteria:

* Histologically confirmed diagnosis of primary non-small cell carcinoma of the lung.
* Patients must be classified post-operatively as Stage IB-IIIB(T3N2M0) on the basis of pathologic criteria after complete surgical resection(R0).
* Complete recovery from surgery and standard post-operative therapy (if applicable) at the time of randomization.
* Confirmation by the central laboratory that the tumour harbours ALK positive.
* At least 1-year life expectancy.
* Eastern Cooperative Group (ECOG) Performance Status score of 0 or 1.
* The laboratory test values should meet the following requirements:

  1. Absolute neutrophil count ≥ 1.5 x 109/L , Platelets ≥ 100 x 109/L ，hemoglobin ≥9g/dL
  2. Total bilirubin≤ 1.5 x institutional upper limit of normal,AST and ALT≤ 2.5 x institutional upper limit of normal
  3. Creatinine≤ 1.5 x institutional upper limit of normal ,if not, Creatinine Clearance ≥ 50 ml/min
  4. International normalized ratio (INR) and prothrombin time ≤1.5 x institutional upper limit of normal; and activated partial thromboplastin time (aPTT) ≤1.5 x institutional upper limit of normal
* Female patients must have a negative pregnancy test at baseline.

Exclusion Criteria:

* Patients who are participating in other clinical studies or are receiving other investigational drugs , or investigational devices within 4 weeks before the first dose of our study drugs. If patients are participating in non-interventional clinical trials, they can be included in this study.
* Patients who have a presence of unresectable or metastatic disease, the pathological diagnosis show the microscopically positive surgical margins or extranodal invasion, or residual disease of surgery，or had only segmentectomies or wedge resections.
* Patients with superior sulcus cancer.
* Patients who have received a surgery with total right lung resection.
* History of other malignancies within 5 years of the first dose of the study drug, except: malignant tumors that can be expected to recover after treatment.
* Prior treatment with other anti-cancer treatments or NSCLC including chemotherapy, radiotherapy, targeted therapy (such as small molecule tyrosine kinase inhibitors targeting EGFR, VEGFR or other pathways, monoclonal antibodies, etc.), immunotherapy, investigational therapy, etc. but except platinum based chemotherapy for adjuvant therapy.
* Major surgery within 3 weeks of the first dose of the study drug.
* Patients who have used traditional Chinese medicines and traditional Chinese medicine preparations with indications for anti-tumor therapy or adjuvant therapy for tumors within 14 days of the first dose of the study drug.
* Patients who have used the following drugs within 14 days before the first dose : strong inhibitors, strong inducers of CYP3A or CYP3A substrates with a narrow therapeutic index.
* Patients who have severe cardiovascular disease.
* Patients with a known allergy to Tartrazine，a dye used in 100mg capsules.
* Severe active infection, interstitial lung disease/pneumonitis, or any serious underlying disease that may interfere with the subject's treatment with the regimen within 2 weeks prior to the first dose of study drug.
* Active HIV virus antibody,Treponema pallidum antibody positive.
* Active hepatitis B, hepatitis C virus antibody positive, or active tuberculosis.
* Presence of active gastrointestinal (GI) disease or other conditions that will interfere significantly with the absorption, distribution, metabolism, or excretion of study drugs.
* According to the judgment of the investigator, other conditions may affect the compliance of the protocol or affect the subject's signing of the informed consent, or is not suitable for participating in this clinical trial.

Where this trial is running

Tianjin

• TianJin Medical University Cancer Institute & Hospital — Tianjin, China (Recruiting)

Study contacts

• Study coordinator: Chang Li Wang, Ph.D

Conditions Non-small Cell Lung Cancer